Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Pfizer

Status

Completed

Conditions

Non-Small Cell Lung Cancer

Treatments

Drug: Crizotinib

Study type

Observational

Funder types

Industry

Identifiers

NCT02679170

A8081057

IDEALKROS (Other Identifier)

IDEALK (Other Identifier)

Details and patient eligibility

About

Prospective observational study to IDEntify patients with advanced/metastatic NSCLC and ALK and ROS1 translocation and to establish their therapeutic management (IDEALK&ROS)

Enrollment

692 patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

For ALK Incidence substudy

Patients with Advanced or metastatic non-small cell lung cancer
Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement
Age > 18 years For ALK treatment substudy (retrospective and prospective)
Age > 18 years
Confirmed anaplastic lymphoma kinase (ALK)-positive tumour
Patients treated with crizotinib under routine clinical practice
Patients with a minimum data registered at the medical history
For the patients that will be recruited prospectively: Patients must have a signed informed consent document.

For the ROS1 treatment sub-study (retrospective only):

Age > 18 years
Confirmation of NSCLC with ROS1-positive translocation
Have been eligible to receive treatment with crizotinib according to routine clinical practice since the market launch of the ROS1 indication in Spain on 8 February 2017 until the opening of the site.
Patients should have a predetermined minimum amount of data recorded in their medical records.

Exclusion criteria